Assertio Holdings, Inc. (ASRT)
USD 0.59
(-6.73%)
USD 0.59
(-6.73%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 286.41 Million USD | -30.8% |
| 2022 | 413.91 Million USD | 26.75% |
| 2021 | 326.54 Million USD | 7.67% |
| 2020 | 303.27 Million USD | -42.47% |
| 2019 | 527.17 Million USD | -43.49% |
| 2018 | 932.86 Million USD | -10.18% |
| 2017 | 1.03 Billion USD | -15.24% |
| 2016 | 1.22 Billion USD | -10.13% |
| 2015 | 1.36 Billion USD | 91.75% |
| 2014 | 711.06 Million USD | 39.79% |
| 2013 | 508.65 Million USD | 259.08% |
| 2012 | 141.65 Million USD | -13.82% |
| 2011 | 164.37 Million USD | 88.87% |
| 2010 | 87.03 Million USD | -4.97% |
| 2009 | 91.58 Million USD | -3.68% |
| 2008 | 95.08 Million USD | 17.9% |
| 2007 | 80.64 Million USD | 53.27% |
| 2006 | 52.61 Million USD | -20.73% |
| 2005 | 66.37 Million USD | 190.26% |
| 2004 | 22.86 Million USD | -52.05% |
| 2003 | 47.69 Million USD | 105.76% |
| 2002 | 23.17 Million USD | 165.0% |
| 2001 | 8.74 Million USD | 0.16% |
| 2000 | 8.73 Million USD | -61.08% |
| 1999 | 22.43 Million USD | 117.81% |
| 1998 | 10.3 Million USD | 123.91% |
| 1997 | 4.6 Million USD | 1433.33% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 279.44 Million USD | -0.89% |
| 2024 Q1 | 281.96 Million USD | -1.56% |
| 2023 Q4 | 286.41 Million USD | -24.63% |
| 2023 Q2 | 405.17 Million USD | -2.2% |
| 2023 FY | 286.41 Million USD | -30.8% |
| 2023 Q3 | 380.02 Million USD | -6.21% |
| 2023 Q1 | 414.27 Million USD | 0.09% |
| 2022 Q2 | 321.97 Million USD | -5.06% |
| 2022 Q4 | 413.91 Million USD | 28.01% |
| 2022 FY | 413.91 Million USD | 26.75% |
| 2022 Q3 | 323.34 Million USD | 0.42% |
| 2022 Q1 | 339.13 Million USD | 3.85% |
| 2021 Q3 | 299.3 Million USD | -4.07% |
| 2021 FY | 326.54 Million USD | 7.67% |
| 2021 Q4 | 326.54 Million USD | 9.1% |
| 2021 Q1 | 325.42 Million USD | 7.3% |
| 2021 Q2 | 312.01 Million USD | -4.12% |
| 2020 Q4 | 303.27 Million USD | -8.87% |
| 2020 Q1 | 219.27 Million USD | -58.41% |
| 2020 Q2 | 345.72 Million USD | 57.67% |
| 2020 Q3 | 332.79 Million USD | -3.74% |
| 2020 FY | 303.27 Million USD | -42.47% |
| 2019 Q1 | 883.46 Million USD | -5.3% |
| 2019 Q2 | 812.87 Million USD | -7.99% |
| 2019 Q4 | 527.17 Million USD | -30.35% |
| 2019 Q3 | 756.86 Million USD | -6.89% |
| 2019 FY | 527.17 Million USD | -43.49% |
| 2018 Q1 | 1 Billion USD | -3.52% |
| 2018 FY | 932.86 Million USD | -10.18% |
| 2018 Q4 | 932.86 Million USD | -5.15% |
| 2018 Q3 | 983.5 Million USD | 7.82% |
| 2018 Q2 | 912.19 Million USD | -8.97% |
| 2017 Q2 | 1.08 Billion USD | -7.98% |
| 2017 Q4 | 1.03 Billion USD | -1.97% |
| 2017 FY | 1.03 Billion USD | -15.24% |
| 2017 Q1 | 1.17 Billion USD | -3.72% |
| 2017 Q3 | 1.05 Billion USD | -2.4% |
| 2016 Q4 | 1.22 Billion USD | -1.95% |
| 2016 Q3 | 1.24 Billion USD | 0.29% |
| 2016 FY | 1.22 Billion USD | -10.13% |
| 2016 Q1 | 1.33 Billion USD | -2.04% |
| 2016 Q2 | 1.24 Billion USD | -6.71% |
| 2015 Q4 | 1.36 Billion USD | 0.06% |
| 2015 Q3 | 1.36 Billion USD | 3.01% |
| 2015 Q2 | 1.32 Billion USD | 87.78% |
| 2015 Q1 | 704.42 Million USD | -0.93% |
| 2015 FY | 1.36 Billion USD | 91.75% |
| 2014 Q1 | 468.7 Million USD | -7.85% |
| 2014 Q2 | 458.48 Million USD | -2.18% |
| 2014 Q4 | 711.06 Million USD | -4.23% |
| 2014 FY | 711.06 Million USD | 39.79% |
| 2014 Q3 | 742.43 Million USD | 61.93% |
| 2013 Q1 | 135.22 Million USD | -4.54% |
| 2013 Q2 | 133.98 Million USD | -0.92% |
| 2013 Q3 | 156.74 Million USD | 16.99% |
| 2013 Q4 | 508.65 Million USD | 224.51% |
| 2013 FY | 508.65 Million USD | 259.08% |
| 2012 Q2 | 143.1 Million USD | -5.82% |
| 2012 FY | 141.65 Million USD | -13.82% |
| 2012 Q1 | 151.95 Million USD | -7.55% |
| 2012 Q4 | 141.65 Million USD | -2.25% |
| 2012 Q3 | 144.91 Million USD | 1.26% |
| 2011 Q2 | 181.26 Million USD | -0.04% |
| 2011 FY | 164.37 Million USD | 88.87% |
| 2011 Q3 | 171.78 Million USD | -5.23% |
| 2011 Q1 | 181.33 Million USD | 108.36% |
| 2011 Q4 | 164.37 Million USD | -4.32% |
| 2010 FY | 87.03 Million USD | -4.97% |
| 2010 Q4 | 87.03 Million USD | -2.74% |
| 2010 Q2 | 85.32 Million USD | 1.32% |
| 2010 Q3 | 89.48 Million USD | 4.87% |
| 2010 Q1 | 84.21 Million USD | -8.05% |
| 2009 Q4 | 91.58 Million USD | -7.01% |
| 2009 Q1 | 105.48 Million USD | 10.94% |
| 2009 Q3 | 98.48 Million USD | 4.88% |
| 2009 Q2 | 93.9 Million USD | -10.98% |
| 2009 FY | 91.58 Million USD | -3.68% |
| 2008 Q4 | 95.08 Million USD | -1.98% |
| 2008 Q1 | 74.06 Million USD | -8.17% |
| 2008 FY | 95.08 Million USD | 17.9% |
| 2008 Q2 | 83.59 Million USD | 12.88% |
| 2008 Q3 | 97 Million USD | 16.04% |
| 2007 Q4 | 80.64 Million USD | 43.42% |
| 2007 FY | 80.64 Million USD | 53.27% |
| 2007 Q2 | 45.8 Million USD | 23.85% |
| 2007 Q3 | 56.23 Million USD | 22.76% |
| 2007 Q1 | 36.98 Million USD | -29.71% |
| 2006 Q4 | 52.61 Million USD | 4.48% |
| 2006 Q3 | 50.36 Million USD | -4.28% |
| 2006 FY | 52.61 Million USD | -20.73% |
| 2006 Q1 | 61.54 Million USD | -7.28% |
| 2006 Q2 | 52.61 Million USD | -14.51% |
| 2005 Q4 | 66.37 Million USD | -5.7% |
| 2005 Q2 | 21.84 Million USD | -41.22% |
| 2005 Q1 | 37.16 Million USD | 62.52% |
| 2005 FY | 66.37 Million USD | 190.26% |
| 2005 Q3 | 70.39 Million USD | 222.21% |
| 2004 FY | 22.86 Million USD | -52.05% |
| 2004 Q2 | 34.84 Million USD | -15.16% |
| 2004 Q4 | 22.86 Million USD | -17.04% |
| 2004 Q3 | 27.56 Million USD | -20.89% |
| 2004 Q1 | 41.07 Million USD | -13.88% |
| 2003 Q4 | 47.69 Million USD | 156.27% |
| 2003 Q3 | 18.61 Million USD | -27.23% |
| 2003 Q2 | 25.57 Million USD | 56.0% |
| 2003 Q1 | 16.39 Million USD | -29.27% |
| 2003 FY | 47.69 Million USD | 105.76% |
| 2002 Q2 | 6.74 Million USD | -46.96% |
| 2002 Q3 | 12.58 Million USD | 86.5% |
| 2002 Q4 | 23.17 Million USD | 84.16% |
| 2002 FY | 23.17 Million USD | 165.0% |
| 2002 Q1 | 12.72 Million USD | 45.46% |
| 2001 Q2 | 14.48 Million USD | 105.33% |
| 2001 Q3 | 11.41 Million USD | -21.17% |
| 2001 Q4 | 8.74 Million USD | -23.41% |
| 2001 FY | 8.74 Million USD | 0.16% |
| 2001 Q1 | 7.05 Million USD | -19.21% |
| 2000 Q2 | 7.48 Million USD | -17.98% |
| 2000 Q3 | 6.19 Million USD | -17.23% |
| 2000 Q4 | 8.73 Million USD | 40.95% |
| 2000 FY | 8.73 Million USD | -61.08% |
| 2000 Q1 | 9.12 Million USD | -59.32% |
| 1999 Q1 | 9.1 Million USD | -11.65% |
| 1999 Q3 | 7.1 Million USD | -13.41% |
| 1999 Q4 | 22.43 Million USD | 215.98% |
| 1999 FY | 22.43 Million USD | 117.81% |
| 1999 Q2 | 8.2 Million USD | -9.89% |
| 1998 FY | 10.3 Million USD | 123.91% |
| 1998 Q1 | 11.5 Million USD | 150.0% |
| 1998 Q2 | 11 Million USD | -4.35% |
| 1998 Q4 | 10.3 Million USD | -0.96% |
| 1998 Q3 | 10.4 Million USD | -5.45% |
| 1997 Q3 | 1.5 Million USD | 0.0% |
| 1997 Q4 | 4.6 Million USD | 206.67% |
| 1997 FY | 4.6 Million USD | 1433.33% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -332.033% |
| Safety Shot Inc | 12.7 Million USD | -2153.639% |
| Bright Green Corporation | 17.4 Million USD | -1545.798% |
| Embecta Corp. | 1.21 Billion USD | 76.415% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 68.331% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -398.831% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 74.948% |
| Dynavax Technologies Corporation | 997.09 Million USD | 71.275% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -39.176% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 60.673% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 81.808% |
| PainReform Ltd. | 9.93 Million USD | -2784.381% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -947.352% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -947.352% |
| SCYNEXIS, Inc. | 128.41 Million USD | -123.047% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1138.458% |
| Journey Medical Corporation | 76.84 Million USD | -272.704% |
| Alpha Teknova, Inc. | 128.58 Million USD | -122.743% |
| Procaps Group, S.A. | 460.18 Million USD | 37.76% |
| Theratechnologies Inc. | 77.76 Million USD | -268.295% |
| Harrow Health, Inc. | 311.75 Million USD | 8.127% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1823.179% |
| Biofrontera Inc. | 27.93 Million USD | -925.415% |
| DURECT Corporation | 45.18 Million USD | -533.825% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 79.672% |
| Cronos Group Inc. | 1.13 Billion USD | 74.748% |
| OptiNose, Inc. | 107.72 Million USD | -165.87% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 39.199% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -411.929% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1142.753% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 37.738% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2303.211% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -250.248% |
| Radius Health, Inc. | 1.71 Billion USD | 83.308% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -437.502% |
| ProPhase Labs, Inc. | 91.92 Million USD | -211.572% |
| Phibro Animal Health Corporation | 982.18 Million USD | 70.839% |
| Procaps Group S.A. | 460.18 Million USD | 37.76% |
| Alvotech | 950.09 Million USD | 69.853% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -561.338% |
| Viatris Inc. | 47.68 Billion USD | 99.399% |
| Rockwell Medical, Inc. | 52.17 Million USD | -448.979% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -142.533% |
| SIGA Technologies, Inc. | 254.83 Million USD | -12.393% |
| Tilray Brands, Inc. | 4.33 Billion USD | 93.393% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -4.646% |
| Shineco, Inc. | 84.17 Million USD | -240.248% |
| PetIQ, Inc. | 868.22 Million USD | 67.011% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -3294.31% |
| Incannex Healthcare Limited | 17.04 Million USD | -1580.172% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 91.191% |
| Alimera Sciences, Inc. | 153.52 Million USD | -86.563% |
| Silver Spike Investment Corp. | 88.57 Million USD | -223.359% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -4712.361% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -747.499% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -816.746% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2062.055% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -9.686% |
| Hempacco Co., Inc. | 18.04 Million USD | -1487.417% |
| Talphera, Inc. | 20.39 Million USD | -1304.359% |
| Alvotech | 950.09 Million USD | 69.853% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 29.481% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 82.653% |
| Currenc Group, Inc. | 141.49 Million USD | -102.43% |
| Kamada Ltd. | 351.96 Million USD | 18.624% |
| Indivior PLC | 1.95 Billion USD | 85.321% |
| Evoke Pharma, Inc. | 7.06 Million USD | -3952.021% |
| Flora Growth Corp. | 23.62 Million USD | -1112.304% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2062.055% |
| Evolus, Inc. | 188.99 Million USD | -51.546% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 77.62% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 81.068% |
| Akanda Corp. | 8.83 Million USD | -3140.037% |